Ignite Creation Date:
2025-12-25 @ 3:19 AM
Ignite Modification Date:
2026-03-14 @ 1:09 AM
Study NCT ID:
NCT03127605
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2020-05-18
First Post:
2017-04-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Inotuzumab Ozogamicin - PF-05208773
Sponsor:
Pfizer
Organization:
Study Overview
Official Title:
None
Status:
APPROVED_FOR_MARKETING
Status Verified Date:
2020-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Inotuzumab Ozogamicin Expanded Access Program
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: